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Abstract
A Trypanosoma cruzi Loopamp kit was recently developed as a ready-to-use diagnostic
method requiring minimal laboratory facilities. We evaluated its diagnostic accuracy for
detection of acute Chagas disease (CD) in different epidemiological and clinical scenarios.
In this retrospective study, a convenience series of clinical samples (venous blood treated
with EDTA or different stabilizer agents, heel-prick blood in filter paper or cerebrospinal fluid
samples (CSF)) from 30 infants born to seropositive mothers (13 with congenital CD and 17
noninfected), four recipients of organs from CD donors, six orally–infected cases after con-
sumption of contaminated guava juice and six CD patients coinfected with HIV at risk of CD
reactivation (N = 46 patients, 46 blood samples and 1 CSF sample) were tested by T. cruzi
Loopamp kit (Tc LAMP) and standardized quantitative real-time PCR (qPCR). T. cruzi Loop-
amp accuracy was estimated using the case definition in the different groups as a reference.
Cohen’s kappa coefficient (κ) was applied to measure the agreement between Tc LAMP
(index test) and qPCR (reference test). Sensitivity and specificity of T. cruzi Loopamp kit in
blood samples from the pooled clinical groups was 93% (95% CI: 77–99) and 100% (95%
CI: 80–100) respectively. The agreement between Tc LAMP and qPCR was almost perfect
(κ = 0.92, 95% CI: 0.62–1.00). The T. cruzi Loopamp kit was sensitive and specific for detec-
tion of T. cruzi infection. It was carried out from DNA extracted from peripheral blood sam-
ples (via frozen EDTA blood, guanidine hydrochloride-EDTA blood, DNAgard blood and
dried blood spots), as well as in CSF specimens infected with TcI or TcII/V/VI parasite
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Author summary
The aim of this study was to evaluate a kit prototype (T. cruzi Loopamp or Tc LAMP)
based on loop-mediated isothermal amplification (LAMP) for molecular diagnosis of
acute Chagas disease in well-characterized individuals, collected in real life conditions,
such as newborns or infants born to Chagas disease mothers aiming to detect congenital
Chagas disease, recipients of organs from Chagas disease donors who acquired T. cruzi
infection after transplantation, persons with oral Chagas disease acquired after consump-
tion of a contaminated meal, and HIV/T. cruzi coinfected patients at risk of Chagas dis-
ease reactivation due to immunosuppression. Different types of clinical samples were
tested; peripheral blood samples treated with ethylenediamine tetraacetic acid (EDTA) as
anticoagulant or with guanidine hydrochloride or DNAgard stabilizer agents, as well as
dried blood spots and cerebrospinal fluid samples. The performance of Tc LAMP was esti-
mated using the case definition in the different groups as a reference and all test kit results
were compared to those obtained using standardized duplex real-time PCR (qPCR) in the
same clinical samples. Sensitivity and specificity of Tc LAMP in blood samples from the
pooled clinical groups were 93% (95% CI: 77–99) and 100% (95% CI: 80–100) respec-
tively. The agreement between Tc LAMP and qPCR was almost perfect (κ index of
Cohen = 0.92, 95% CI: 0.62–1.00). Tc LAMP was sensitive and specific for detection of
T. cruzi infection in the tested samples, encouraging prospective field studies to validate
its use for rapid detection of T. cruzi infection in congenital, acute and CD reactivation
due to HIV infection.
Introduction
Chagas disease (CD), also known as American trypanosomiasis, is a neglected tropical disease
caused by the protozoan parasite Trypanosoma cruzi that affects about 6 to 7 million people
worldwide, mainly in endemic areas of 21 Latin American countries [1].
Transmission of T. cruzi occurs by the vectorial route, including oral transmission by con-
suming food or beverages contaminated with triatomine faeces, by congenital transmission,
blood transfusion or solid organ transplantation from infected donors, and by laboratory
accidents.
The disease evolves from an acute phase when the infection is acquired, which is frequently
asymptomatic, to a chronic phase that may develop, in up to 30% of cases, cardiac disease, and
in 10% of cases digestive mega-syndromes, neurological and/or mixed complications [2,3]. A
proportion of chronically yet asymptomatic infected people, facing an immunocompromised
condition due to HIV infection, organ transplantation, autoimmune disease, or oncologic
treatments, may experience CD reactivation, evolving to severe clinical forms of the disease
with high parasitemia [4].
Early diagnosis of infection is crucial in cases of any acute infections, because it allows
prompt and timely trypanocidal treatment, reducing morbimortality of severe clinical presen-
tations of CD and progression to symptomatic chronic infections [5–8]. However, traditional
parasitological methods currently used for diagnosis in the abovementioned clinical settings
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have poor performance. In fact, microscopy observation is highly operator dependent and low
sensitive, haemoculture and xenodiagnoses are cumbersome methods that may take several
months before a result can be reported. On the other hand, serological assays for T. cruzi infec-
tion are not always applicable; for serodiagnosis of infants born to seropositive mothers it is
necessary to wait until at least nine months of age [9], and in severely immunocompromised
CD patients, false seronegative results may be obtained [4].
Molecular methods, particularly polymerase chain reaction (PCR), have been employed as
an alternative to improving current diagnostic algorithms; however, most rural endemic areas
do not have the infrastructure needed for PCR analysis [7,10–12]. In this context, the loop-
mediated isothermal amplification method (LAMP) may offer the advantage of PCR but only
requiring simple laboratory manipulations without the need for expensive equipment [13–15].
The feasibility to use a LAMP prototype kit for detection of acute T. cruzi infections has been
reported [15].
The present study aimed to evaluate the performance of T. cruzi Loopamp in panels of clini-
cal samples from acute CD patients belonging to clinical settings of high vulnerability, in




Informed written consent was obtained from seropositive mothers, whose infants´ samples
were included in the study after receiving permission from the institutional review board
(IRB) of the Centro de Educación Médica e Investigaciones Clı́nicas “Norberto Quirno”
(CEMIC), Buenos Aires, IRB 00001745- ORG 0001315, HHS, 10 July 2013). In the case of Cha-
gas-HIV patients, the use of samples was authorized by the IRB of the Hospital A. Posadas and
Hospital de Enfermedades Infecciosas “Dr. Francisco J. Muñiz” without written consent from
patients (IRB notes NI4015/17 y NI012/18), in agreement with Argentine legislation in force at
this time (Blood Donation Law N˚ 22990, Res. N˚1409/15).
The use of archival samples from recipients of organs from infected donors was authorized
by the IRB committees of Hospital Británico, Hospital Austral, and Hospital Alemán of Buenos
Aires because permission to use samples for research purposes was included in the written
informed consent form signed by patients when admitted for routine medical checkups.
The use of archival samples from cases of CD outbreak via oral transmission at Chichiri-
viche de la Costa, Venezuela was authorized by the Scientific Ethics Committee of the “IMT,
Universidad Central de Venezuela”, as reported in Noya et al. [16]. After reading the terms of
free and informed consent, each patient or legal representative signed the form and agreed to
sample collection and physical and other para-clinical exams.
Clinical samples
Tc LAMP (index test) was compared with standardized qPCR (comparator test) using panels of
archival DNA samples that were extracted from clinical specimens of patients affected by congen-
ital, acute T. cruzi infections or Chagas disease reactivation, belonging to the following groups:
Group I: Congenital CD (cCD). This panel was formed of archival DNA from blood
samples collected at the time of diagnosis from 30 babies (9 newborns and 21 infants) born to
seropositive mothers in Argentina between 2013 and 2017. According to the gold standard
diagnosis, i.e. parasitaemia detected by micromethod during the first months of life and/or
positive serology during 10–12 months of life, 13 (43.3%) babies were confirmed as cCD and
17 (56.7%) were not infected by T. cruzi. All cCD cases detected by means of gold standard
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diagnosis were referred for treatment with Benznidazole following national guidelines [17]. In
26 cases, 1.5 mL of venous blood (VB) was collected by venepuncture in EDTA vacuum tubes
and 1 mL VB was transferred to microtubes containing 250 μL of a commercial stabilizer
(DNAgard, Biomatrica, San Diego, USA, proportion 1:4) for molecular analysis. The mixture
was conserved at room temperature for no more than one year and afterwards it was stored at
4˚C for a maximum period of two years, until DNA extraction, which was then stored at -20˚C
up until doing qPCR and Tc LAMP analyses. In the other four cCD newborns (Hospital A.
Posadas, Buenos Aires), heel-prick dried blood spot (DBS) samples were collected onto What-
man 903 filter papers following the guidelines of the national program for screening diseases
in newborns (Argentine Law 23.413/23.874).[18] Each DBS card [19] contained six spots with
around 50 μL of heel-prick blood each. The cards were dried for at least 3 hours after blood
collection and packed individually in zipped bags to be transported by courier at room temper-
ature to the molecular biology laboratory. Upon reception, the zipped bags were stored at
-20˚C between 5 and 18 months until molecular analysis.
The micromethod was performed as described by Rissio et al. [20] and the serological anal-
yses were carried out using two different commercial assays following the recommendations
of the manufacturers, namely, Chagatest ELISA recombinante v.3.0 (Wiener Lab, Rosario,
Argentina) and Indirect Hemagglutination (IHA), Chagatest HAI (Wiener Lab, Rosario,
Argentina). Because at least two positive serological tests are necessary to consider a patient to
be infected, as recommended by WHO and PAHO [21], in cases of inconclusive serological
results, an indirect immunofluorescence (IFI, Inmunofluor Chagas, Biocientı́fica, S.A., Argen-
tina) test was performed, following manufacturer instructions.
Group II: Orally-transmitted CD (oCD). Blood samples from six patients residing in
Chichiriviche de la Costa, Vargas State, Venezuela, who were diagnosed with orally-transmit-
ted CD after consumption of T. cruzi-contaminated guava juice in March 2009, were evaluated
by Tc LAMP and qPCR. The patients were admitted and followed up at the “Instituto de Medi-
cina Tropical”, “Universidad Central de Venezuela”, Caracas, Venezuela[16]. Parasitological
diagnosis was done either by microscopical search of trypomastigotes in peripheral blood or
by parasite culture, and serological analysis was performed by in-house assays (ELISA and
IHA) with a T. cruzi epimastigotes delipidized antigen for the detection of anti-human IgG
and IgM. Clinical examination included electrocardiogram and echocardiography. The
patients received supervised treatment with 7mg/kg/day of Benznidazole for 60 days. For
molecular diagnosis, 5 mL of blood samples were collected in 5 mL of Guanidine hydrochlo-
ride solution, 6M EDTA 0.2 M, pH 8.00 (GE) and stored at 4˚C.
Group III: Organ recipients from infected donors (Tx-RID). The Tx-RID group was
composed of four seronegative individuals who received organ transplants (kidney and/or
liver) from T. cruzi-infected donors. Their infection was diagnosed by qPCR and/or Strout
analyses, as described previously by Cura et al. [6]. All Tx-RID patients were treated with try-
panocidal drugs, following the recommendations of the Argentinean Society of Infectiology
[22]. For the molecular analysis of samples obtained between 2015–2017 in Buenos Aires, 5
mL of blood were collected in EDTA vacuum tubes and stored at -20˚C during a maximum
period of three years until processing for qPCR and Tc LAMP was done.
Group IV: Chagas disease and HIV coinfected patients (Chagas-HIV). Seven clinical
samples—EDTA-treated blood (EB, n = 2), guanidine hydrochloride-EDTA blood (GEB,
n = 1), peripheral blood stored on Whatman 903 filter paper spots (DBS, n = 3) and cerebro-
spinal fluid samples (CSF, n = 1)—were obtained from six T. cruzi-HIV chronically coinfected
patients with confirmed diagnosis for central nervous system (CNS) CD reactivation. The
patients were admitted and clinically monitored at the Hospitals Francisco Muñiz and Alejan-
dro Posadas, Buenos Aires, between 2014 and 2018. Diagnosis included microscopical analysis
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of the CSF specimens, use of the Strout method (parasitological blood test), and CNS imaging.
In addition, in three patients admitted at Hospital Posadas, conventional satellite DNA and
kDNA-based PCR tests were performed from DBS samples. The patients were treated with
5–7 mg/kg/day of Benznidazole. The CSF sample was collected in a microtube with O-ring
caps and stored at -20˚C during a maximum period of two years.
Molecular detection of T. cruzi DNA
The Tc LAMP prototype was compared with standardized qPCR in panels of DNA samples
extracted from clinical specimens of patients belonging to the clinical groups described above
[10].
DNA extraction from clinical specimens. Nucleic acids were extracted from 200 μL ali-
quots of EDTA-blood or CSF samples, or from 300 μL of guanidine hydrochloride-EDTA
blood or DNAgard blood using the High Pure PCR Template Preparation Kit (Roche, Ger-
many). Before lysis, 5μL of 40 pg/μL linearized pZero plasmid was added as an internal ampli-
fication standard except for the oCD samples; each sample was then purified following
manufacturer recommendations [23]. DNA extraction from DBS was carried out following
the method reported by Walter and coworkers using the Roche kit [24]. For each patient card,
three punches (3 mm diameter each) were taken and pooled into a sterile Eppendorf tube and
200 μL of lysis buffer were added. Following incubation with proteinase K for 3 hours at 55˚C,
DNA extraction was done according to manufacturer instructions and 50 μL of eluate was
obtained. The DNA extracts from clinical samples were conserved at -20˚C until their use for
Tc LAMP and qPCR.
Trypanosoma cruzi prototype kit. Tc LAMP (index test) was the prototype kit developed
by Eiken Chemical Co., Ltd. Japan, using as molecular target the repetitive satellite DNA
sequence of T. cruzi as previously reported [15]. The reagents are in dried form on the inside
of the cap of the reaction tube and are stable for one year at 30˚C.
The LAMP reaction was standardized from 5 μl of DNA lysates from Group cCD patients
due to sample volume restrictions in studies of newborns, while for the remaining groups in
the study, the maximum volume recommended by the manufacturer (30 μl of DNA eluate)
was used [15].
Each LAMP tube was flicked down to collect the solution at the bottom and placed upside
down for two minutes to reconstitute the dried reagent, inverted five times to mix the contents
followed by a spin down. The reaction tube contains calcein in a quenched state, bound to
manganese ions. Once the LAMP reaction starts, pyrophosphate ions that are generated bind
to the manganese ions, so calcein is released generating fluorescent light. Incubation of the
reaction was carried out at 65˚C for 40 minutes for isothermal amplification, followed by a
step at 80˚C for five minutes for enzyme inactivation using a Rotor Gene 6000 thermocycler
(Corbett Life Science, Cambridgeshire, UK).
LAMP results are qualitative and are therefore expressed as positive (Pos) and negative
(Neg), based on direct eye visualization [15]. One replicate was carried out per clinical sample.
Sample panels were masked, and a series of six samples each were randomly chosen from all
the panels to perform a LAMP round. Each round included a negative control (non-template
control (NTC), distilled water) provided in the kit and a positive control (30 μL of 1fg/μL CL
Brener stock (Tc VI) DNA). A LAMP operator read the results blinded to qPCR results and to
the clinical data.
Quantitative real-time PCR (qPCR). Duplex real-time qPCR using TaqMan probes tar-
geted to T. cruzi satellite DNA, plus an internal amplification control (IAC), was carried out in
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an ABI7500 thermocycler (Applied Biosystems, Foster City, CA, USA) following standardized
conditions previously reported [10,11].
All reactions included a strong positive control (SPC): 10 fg/ul of CL Brener DNA and a
weak positive control (WPC): 1 fg/uL of CL Brener DNA. The qPCR results were expressed as
positive if the cycle threshold (Ct) was lower than 40 and negative or non-detectable if no Ct
was obtained. The qPCR experiments were done on duplicates per each DNA extract and the
mean value of parasitic load from the duplicates was obtained. An indeterminate result for the
qPCR was defined if IAC amplification gave an outlier Ct value after application of Tukey cri-
teria, as reported by Duffy et al. [10]. Parasitic load was expressed in parasite equivalents/mL
of sample (par. eq/mL). Laboratory operators of the qPCR assay were blinded to index test
results and assayed a series of ten to twelve DNA samples per round. The research evaluator
had no access to the Tc LAMP results nor to clinical information before the end of sample pro-
cessing and reporting.
Quality control samples. In order to establish standard curves for qPCR, human seroneg-
ative blood samples (certified by a blood bank) were spiked with 0.5, 1, 10, 100, 1000, 10000
cultured cells of CL Brener (TcVI) for cCD, Tx-RID, Chagas-HIV groups because TcII/V/VI
populations have been identified in most patients residing in Argentina [23, 25–28]. The TcVI
strain harbors a similar copy dosage of the satellite DNA target sequence than TcII and TcV
strains [23]. In contrast, seronegative blood spiked with 0.5, 1, 10, 100, 1000, 10000 Silvio X-10
(TcI) cultured cells was used for quantification of oCD group because TcI is the prevailing dis-
crete typing unit (DTU) in Venezuela and harbors around one order of magnitude fewer num-
ber of copies than TcII, V and VI strains [29]. DNAgard seronegative-spiked blood was used
to quantify cCD group samples, except those collected in DBS, which were not quantitated.
Guanidine hydrochloride EDTA seronegative spiked blood was used for samples collected in
guanidine hydrochloride EDTA buffer (oCD and some Chagas-HIV samples). The oCD and
DBS samples were checked for DNA integrity. The oCD samples were tested using TaqMan
RNase P Detection Reagents Kit (Thermo Fisher Scientific, Waltham, Massachusetts USA),
following the guidelines of the manufacturer. The DNA quality of the DBS samples was
checked by conventional amplification of β-actin gene, using primers ACT forward 5’-
GGACCTGACTGACTACCTCATGGA-3 and ACT reverse 5’-GATCCACATCTGCTGGAA
GGTGG-3’ to obtain a 550 bp fragment. Reaction was carried out in 25 μL of final volume con-
taining 1X buffer, deoxynucleotide triphosphate (dNTP) 0.2 mM, 0.4 μM primers, MgCl2 2.5
mM, Taq Polymerase 1U and 5 μL of DNA eluate. Cycling was a first cycle at 94˚C for 45 sec.
followed by 35 cycles at 94˚C for 20 sec, 62˚C for 10 sec and 72˚C for 20 sec, with a final step at
72˚C for 45 sec.
Statistical analysis
The Tc LAMP and qPCR data obtained from the blood samples (venous blood treated with
EDTA or different stabilizer agents, heel-prick blood in filter paper) from the different groups
of patients were pooled to estimate the accuracy of the T. cruzi Loopamp kit and the agreement
between Tc LAMP and qPCR. The CSF samples were excluded from these analyses. The sensi-
tivity and specificity of Tc LAMP were estimated using the case definition in the different
groups as a reference (e.g. microscopy observation using the micromethod and serology for
cCD; microscopy observation using the micromethod, culture and serology for oCD, and
qPCR and/or Strout analysis for Tx-RID and Chagas-HIV patients). Cohen’s kappa coefficient
(κ) was applied to measure the agreement between Tc LAMP and qPCR. The sensitivity and
specificity estimates and their 95% exact binomial confidence intervals, as well as the Cohen
kappa statistics, were calculated using the package epiR in R 3.5.0 [30].
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Results
Comparison of Tc LAMP and qPCR in paired samples for detection of T.
cruzi infection
Tc LAMP results obtained in this study were detected by naked-eye visualization, as exempli-
fied in Fig 1.
Group I: Congenital CD (cCD). Tc LAMP and qPCR detected T.cruzi DNA in nine VB
and four DBS samples from all 13 cCD cases whereas VB samples from all 17 non-infected
infants born to seropositive mothers were negatives (Table 1). Positive quantified blood sam-
ples had between 5.27 and 3063.47 par.eq/mL, using as a standard curve DNA obtained from
seronegative blood spiked with CL Brener clone.
Group II: Orally-transmitted CD (oCD). Guanidine hydrochloride-EDTA blood sam-
ples were available from six patients with oCD. Five of them were children and all six presented
cardiac manifestations at the time they were diagnosed; echocardiograms showed pericardial
effusion in all the children, but related symptoms, such as dyspnea or precordial pain, were
not present. Their EKGs were abnormal, showing mainly alteration of the repolarization
(Table 2).
Five cases were concordantly positive by Tc LAMP and qPCR, while patient oCD5 was not
detected by Tc LAMP. The sample showed only 0.003 par.eq/mL by qPCR, indicating very low
parasitic load.
Group III: Recipients of organs from infected donors (Tx-RID). Tc LAMP was tested
in EDTA-blood samples from four seronegative recipients of organs explanted from seroposi-
tive donors. In these cases, qPCR was interpreted as indicator of infection. Except the sample
from case Tx-RID 3, the other three were Tc LAMP positive, presenting parasitic loads ranging
Fig 1. Visualization of Loopamp Trypanosoma cruzi results by the naked eye. Tube 1: NTC control: Tc LAMP reagents with distilled water and
no template; tubes 2–4: cCD cases 1, 5 and 9 (Table 1); tubes 5–6: oCD cases 5 and 6 (Table 2); tube 7: Tx-RID 1 (Table 3); Tube 8: Positive
control: 30 μL of 1fg/μL CL Brener T. cruzi stock (Tc VI) DNA.
https://doi.org/10.1371/journal.pntd.0008402.g001
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Table 1. Detection of T.cruzi DNA in infants born to seropositive mothers using Tc LAMP and qPCR.
Cases
ID
























cCD1 Nav Neg (63) 0.759 Ɛ 64 Reactive (336) cCD Not treated VB (336) Pos Pos 5.27
cCD2 Nav Pos (87) 0.015 ß NR Non Reactive-
treated (600)
cCD Completed VB (87) Pos Pos 3683.8
cCD3 Nav Neg (36) 2.985 ß 256 Reactive (368) cCD Not treated VB (36) Pos Pos 356.19
cCD4 Nav Pos (10) 0.036 ¥ NR Non Reactive-
treated (275)
cCD Completed VB (10) Pos Pos 640.98
cCD5 Nav Pos (49) 2.501 ß 256 Reactive (322) cCD Not treated # VB (49) Pos Pos 37.47
cCD6 Nav Pos (8) 2.624 § 256 Reactive (303) cCD Not treated
##
VB (303) Pos Pos 3063.47
cCD7 Neg (1) Neg (41) 2.531 ß 128 Reactive (427) cCD Not treated VB (41) Pos Pos 53.35
cCD8 NAv Neg (45) 1.418 ¥ 256 Reactive (331) cCD Not treated VB (45) Pos Pos 81.96
cCD9 Pos (1) Neg (44) 0.059 ¥ NR Non Reactive-
treated (324)
cCD Completed VB (44) Pos Pos 12.96
cCD10 Pos (2) NA Nav NR Non Reactive-
treated (Nav)
cCD Completed DBS (2) Pos Pos NA
cCD11 Pos (2) NA Nav NR Non Reactive-
treated (Nav)
cCD Completed DBS (2) Pos Pos NA
cCD12 Pos (2) NA Nav NR Non Reactive-
treated (Nav)
cCD Completed DBS (2) Pos Pos NA
cCD13 Pos (2) NA Nav NR Non Reactive-
treated (Nav)
cCD Completed DBS (2) Pos Pos NA
cCD14 Nav Neg (10) 0.016 § NR Non Reactive
(435)
Non Infected NA VB (435) Neg Neg NA
cCD15 Nav Neg (104) 0.036 ¥ NR Non Reactive
(306)
Non Infected NA VB (104) Neg Neg NA
cCD16 Nav Neg (112) 0.014 ß NR Non Reactive
(312)
Non Infected NA VB (312) Neg Neg NA
cCD17 Nav Neg (64) 0.015 ß NR Non Reactive
(350)
Non Infected NA VB (64) Neg Neg NA
cCD18 Nav Neg (40) 0.016 ß NR Non Reactive
(319)
Non Infected NA VB (40) Neg Neg NA
cCD19 Nav Neg (30) 0.039 ¥ NR Non Reactive
(304)
Non Infected NA VB (304) Neg Neg NA
cCD20 Neg (1) Neg (31) 0.038 ¥ NR Non Reactive
(304)
Non Infected NA VB (31) Neg Neg NA
cCD21 Neg (2) Neg (33) 0.015 ß NR Non Reactive
(306)
Non Infected NA VB (2) Neg Neg NA
cCD22 Neg (1) Neg (62) 0.022 ¥ NR Non Reactive
(321)
Non Infected NA VB (321) Neg Neg NA
cCD23 Nav Neg (122) 0.018 ß NR Non Reactive
(326)
Non Infected NA VB (326) Neg Neg NA
cCD24 Nav Neg (60) 0.036 ¥ NR Non Reactive
(304)
Non Infected NA VB (304) Neg Neg NA
cCD25 Nav Neg (28) 0.014 ß NR Non Reactive
(307)
Non Infected NA VB (28) Neg Neg NA
cCD26 Neg (2) NA 0.014 ß NR Non Reactive
(305)
Non Infected NA VB (2) Neg Neg NA
cCD27 Neg (2) NA 0.012 ß NR Non Reactive
(329)
Non Infected NA VB (2) Neg Neg NA
(Continued)
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from 11.5 to 4060.5 par.eq/mL, using as a standard curve DNA obtained from seronegative
blood spiked with CL Brener clone (Table 3). The discordant Tc LAMP negative and qPCR
positive sample from case Tx-RID 3 had only 0.5 par.eq/mL, indicating very low parasitic load.
Group IV: Chagas disease and HIV coinfected patients (CD-HIV). All six CD-HIV
patients gave positive Tc LAMP and qPCR results in peripheral blood and/or CSF samples col-
lected at the time CD reactivation was suspected (Table 4).
Sensitivity, specificity and agreement
Fig 1 illustrates examples of Tc LAMP results obtained from blood specimens of study cases,




























cCD28 Neg (2) NA 0.014 ß NR Non Reactive
(346)
Non Infected NA VB (2) Neg Neg NA
cCD29 Neg (2) NA 0.017 ß NR Non Reactive
(356)
Non Infected NA VB (2) Neg Neg NA
cCD30 Neg (1) NA 0.071¥ NR Non Reactive
(316)






Mtnity: maternity service. H.Ctr: health center. M: male; F: female; MD: missing data; VB: venous blood containing 25% of DNAgard stabilizer; DBS: dried blood spot;
Nav: sample not available; NA: not applicable; Pos: positive; Neg: negative; p.e/mL: parasite equivalents/milliliter.
� The criterion for serological reactivity was based on at least two positive serological tests.
�� For PCR quantification, the standard curve consisted of DNA obtained from seronegative human blood spiked with known amounts of CL Brener cultured parasites
(TcVI).
# The patient did not complete treatment;
## Comorbidities: bronchiolitis and nosocomial infection.
https://doi.org/10.1371/journal.pntd.0008402.t001
Table 2. Detection of oral infection of T.cruzi by means of Tc LAMP and qPCR.
oCD case Age (years) Clinical manifestations Echo / EKG Tc LAMP Sat qPCR DNA
Result Load� (p.e/mL)
oCD1 10 Cardiac Pericardial effusion/ Altered Pos Pos 10.44
oCD2 8 Cardiac Pericardial effusion/ Altered Pos Pos 0.56
oCD3 9 Cardiac Pericardial effusion/ Altered Pos Pos 122.72
oCD4 36 Cardiac/HIV seropositive Pericardial effusion/ Altered Pos Pos 80.54
oCD5 7 Cardiac Pericardial effusion/ Altered Neg Pos 0.003
oCD6 9 Cardiac Pericardial effusion/ Altered Pos Pos 0.09
M: male; F: female; HIV: Human Immunodeficiency Virus; Echo: Echocardiogram; EKG: Electrocardiogram; Pos: positive; Neg: negative; p.e/mL: parasite equivalents/
milliliter;
� For qPCR quantification, the standard curve was DNA from seronegative human blood spiked with known amounts of Silvio X 10 clone (TcI).
https://doi.org/10.1371/journal.pntd.0008402.t002
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The limited number of samples per group precluded estimating the accuracy of Tc LAMP
for each group. Therefore, the sensitivity and specificity of Tc LAMP were estimated pooling
the data obtained from the 46 blood samples: 29 samples from confirmed Chagas disease cases
(13 cCD, 6 oCD, 4 Tx-RID, and 6 Chagas-HIV) and 17 samples from non-infected cases, all
non-infected infants born to seropositive mothers. These results are summarized in Fig 2.
The sensitivity of Tc LAMP was 93% (95% CI: 77–99) and its specificity was 100% (95% CI:
80–100). The agreement between Tc LAMP and qPCR was almost perfect (κ = 0.92, 95% CI:
0.62–1.00) as only two samples that resulted in Tc LAMP negative were qPCR positive (oCD5,
Table 2 and Tx-RID 3, Table 3.
Discussion
Our approach to the evaluation of a LAMP assay for diagnosis of Chagas disease has been
guided by the knowledge of the resource-limited settings where this neglected disease is still
endemic as well as the insufficient investment of resources allocated to the control of CD
transmission, including in non-endemic countries. Evidence clearly demonstrates that early
diagnosis and treatment results in effective parasite eradication and a reduction in loss to
Table 3. Detection of acute infection in blood samples from seronegative recipients of organs from T.cruzi infected donors.
Case ID Age (years) Time after Tx (days) Tx-organ Receptor Serology Organ Donor Serology Tc LAMP Sat qPCR
Result Load� p.e/mL
Tx-RID 1 71 63 Liver Non Reactive Reactive Positive Positive 11.5
Tx-RID 2 20 MD Kidney Non Reactive Reactive Positive Positive 2939.5
Tx-RID 3 63 MD Liver- Kidney Non Reactive Reactive Negative Positive 0.5
Tx-RID 4 55 69 Liver Non Reactive Reactive Positive Positive 4060.5
M: male; F: female, MD: missing data; p.e/mL: parasite equivalents/milliliter
https://doi.org/10.1371/journal.pntd.0008402.t003
Table 4. Tc LAMP and qPCR detection of reactivation in CD-HIV patients.
Case ID Age
(years)


















EB Pos Pos 107
CD-HIV2 55 Sensory impairment/marked cerebral cortex




CSF Pos Pos 3511.5
EB Pos Pos 143
CD-HIV3 39 Right hemiparesis, facio-brachio-crural/
encephalitis with large space occupying lesion
and brain midline shift
10 Yes Strout positive GEB Pos Pos 677
CD-HIV4 12 Non-Hodgkin Lymphoma/cardio-respiratory
failure; without encephalitis
93 Yes Strout positive DBS Pos Pos 44
CD-HIV5 61 Space-occupying lesion/ vascular and non-
vascular encephalic lesions in NMR
43 Yes Strout negative DBS Pos Pos 47.5
CD-HIV6 48 Space-occupying lesion/ multiple hypodense
brain images on CAT scan
63 No Strout positive DBS Pos Pos 10.5
HIV: human immunodeficiency virus; M: male; F: female; CNS: central nervous system; CSF: cerebrospinal fluid; EB: EDTA-treated blood; GEB: guanidine EDTA-
treated blood. DBS: Dried blood spot. p.e/mL: parasite equivalents/milliliter. NMR: Nuclear Magnetic Resonance. The criterion for risk of reactivation in HIV subjects is
CD4 counts < 200 cells/mL
https://doi.org/10.1371/journal.pntd.0008402.t004
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Fig 2. Flow of participants. aCD: acute Chagas disease; Index Test: Tc LAMP; Reference Test: qPCR.
https://doi.org/10.1371/journal.pntd.0008402.g002
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follow-up of the patient. The T. cruzi Loopamp assay showed high values of sensitivity, speci-
ficity and agreement with qPCR in the following clinical settings:
i) Congenital infection: Even if the accuracy of Tc LAMP per clinical group is not pre-
sented, it should be noted that both the sensitivity and specificity of Tc LAMP in the cCD
group were 100% (13 cases and 17 non-cases correctly diagnosed by Tc LAMP), with complete
agreement with qPCR results (Table 1). The current parasitological/serological diagnostic
algorithm remains unsatisfactory due to the poor sensitivity and operator dependence of para-
sitological methods, along with loss to follow-up, once the mother-newborn pair has left the
maternity service. This loss to follow-up and diagnosis opportunity may reach 55–80%
depending on the geographic area [20,31–35]. In our panel of samples, there were two cases
(cCD3 and cCD7, Table 1) that had negative micromethod results with positive molecular
findings in the same blood collection, indicating the higher sensitivity of molecular methods
and the inadequate performance, due to operator dependency, of the parasitological method
even in samples with high parasitic loads (cCD3: 356.19 par.eq/mL).
Several studies using different in-house PCR methods depicted better performance than the
current diagnostic cCD algorithm [36–39]. However, evaluation of commercial methods suit-
able for clinical practice are urgently needed and there are only a few reports on the use of
nucleic acid amplification kits [9,15,40,41]. Our data show the diagnostic potential of the
Loopamp Trypanosoma cruzi prototype kit for early detection of congenital transmission.
ii) Orally-infected CD: This route of transmission, associated with the consumption of food
contaminated with triatomine feces or didelphid secretions leading to high morbidity and
mortality rates in endemic areas, has been remarkable in the last decade [16,42,43]. In most
outbreaks, molecular tools have been fundamental for specific diagnoses [44–47]. The oral out-
break under study took place mainly in school populations from Chichiriviche de la Costa, a
rural and touristic seashore community located on the central Venezuelan coast. It affected 89
persons, with 5 deaths. Frequency of symptomatic patients was high (89.9%), with long-stand-
ing fever in 87.5%; 82.3% had pericardial effusion detected by echocardiogram and 41% had
EKG abnormalities [16]. The availability of a LAMP kit that could be used in health facilities
close to rural areas where these oral outbreaks can take place would be of great benefit for
rapid screening of people suspected of infection, thus allowing prompt treatment.
iii) In the immunocompromised condition, prompt treatment prevents life-threatening
complications so early detection of infection is critical to improve patient management [4, 6,
48, 49]. Tc LAMP was able to detect parasite DNA in EDTA-blood, guanidine hydrochloride-
EDTA blood, and dried blood spots collected in filter paper, as well as in CSF samples.
The accuracy of Tc LAMP to diagnose different acute forms of CD was excellent (93% sen-
sitivity and 100% specificity). These estimates were obtained combining the results from
samples of the different groups of patients (n = 46), as the number of samples analyzed per
group was limited and only 17 of those were non-cases. The Tc LAMP clinical sensitivity and
specificity estimates reported are important, as samples from acute CD cases have similar char-
acteristics, i.e. high parasitemia and diagnostic approach (microscopy observation, PCR). Fur-
thermore, the samples from these patients are rare and difficult to obtain and the results of this
study prove the value of the T. cruzi Loopamp kit as a diagnostic tool for congenital, acute and
CD reactivation cases. A Chagas disease surveillance study carried out in the endemic prov-
inces of Northern Argentina showed 100% of specificity for Tc LAMP performed in blood
samples from 59 non-infected seronegative adult participants (S1 Table). Another LAMP
study on cCD samples showed high agreement between parasitological observation and Tc
LAMP results [14].
In most of the samples, Tc LAMP and qPCR results were concordant. The two Tc LAMP-
negative samples that were positive by qPCR presented parasitic loads close or below the
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analytical limit of detection of the methodology [10, 11]. Tc LAMP-negative DNA samples
appeared adequate in integrity and did not contain inhibitors for qPCR as seen by amplifica-
tion of the endogenous human RNase P gene (oCD group), β-actin PCR (DBS from cCD and
CD-HIV cases) and IAC (rest of the Groups).
Our previous analytical study using this LAMP assay was carried out with purified DNA
from reference T. cruzi strains belonging to the different DTUs and showed no significant dif-
ferences in analytical sensitivity among them [15]. In the present work, we were able to detect
infection in clinical samples that were shown to be infected by TcI (oCD Group) and TcV pop-
ulations (cCD group) [29, 40].
Tc LAMP was carried out using DNA samples obtained from a variety of sample supports
and stabilizing agents, such as frozen blood treated with EDTA or with GE buffer, blood
treated with DNAgard stabilizer agent, DBS in Whatman filter paper used for the National
Neonatal Screening Program, as well as from CSF specimens. It is expected that this technique
will work also for testing skin, endomyocardial, and/or brain biopsy or necropsy tissue sections
for rapid confirmation of presumptive CD reactivation [25]. The approximate cost of the Tc
LAMP kit is at least one half of the cost of a qPCR kit. Its final cost will depend on the chosen
DNA extraction method and on transportation and customs costs in the countries. As a result,
the next steps towards optimization of standard operating procedures using Tc LAMP should
include the development of more simple DNA extraction methods without loss of sensitivity,
and field validation of the assay in the context of primary health centers and point-of-care lab-
oratories [12,50].
Conclusions
Tc LAMP is a potentially useful rapid laboratory tool for the diagnosis and treatment monitor-
ing of T. cruzi acute infections and cases of reactivation. Its advantages are that no complex
laboratory infrastructure is needed, allowing its application in healthcare facilities with limited
equipment, and giving results rapidly through detection by naked eye.
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